SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?


To: scaram(o)uche who wrote (396)1/27/2003 1:33:52 PM
From: Czechsinthemail  Respond to of 598
 
Nice announcement on T131, and good to hear that they will be following it up with a presentation at USB Piper Jaffray Thursday morning. So far the market response has been "Yawn-minus".

It sounds like its competitive advantages would be in reduced side effects with "an excellent safety profile" unless there is something in "superior potency, equal efficacy" that I'm missing. Given the huge market for Type II diabetes, this one could be huge for TLRK.